AMAG Pharmaceuticals hired Greg Madison as evp and CCO...CytoDyn appointed Sam Zakhem as Middle East business consultant...Health Discovery promoted John Norris as its new CEO...Relypsa named Paul J. Hastings and David W. J. McGirr to its board of directors.
NewLink Genetics added Brian Wiley as cp of business development...Christopher S. Destro joined Atossa Genetics as vp of sales and marketing...Bruce E. Schneider, Ph.D., is now CEO at Omni Bio Pharmaceutical...CytRx promoted Daniel Levitt, M.D., Ph.D., to evp.
ImmunoCellular Therapeutics appointed Gary S. Titus to its board of directors...TVAX Biomedical added Philip Haworth, Ph.D., as CEO...Ambrx named Lawson Macartney, Ph.D., as president, CEO, and to its board of directors...Orgenesis hired Sav DiPasquale as president and CEO...Alexza Pharmaceuticals appointed J. Kevin Buchi to its board of directors...Rolland Carlson, Ph.D., is now president and CEO of Asuragen.
CorMedix promoted Randy Milby to CEO and Richard M. Cohen to CFO...Coherus BioSciences named V. Bryan Lawlis Jr., Ph.D., as chairman of its scientific advisory board...Omicia appointed Mike Aicher as CEO and to its board of directors...Hookipa Biotech appointed Stanley Plotkin, M.D., Michael Mach, Ph.D., Arnaud Marchant, M.D., Ph.D., and Franz Heinz, Ph.D., to its scientific advisory board; Paul-Henri Lambert, Ph.D., as chair of the board; and Thomas Monath, M.D., as CMO.
Savient Pharmaceuticals named David Meeker, M.D., to its board of directors...Joan E. Shaw is now with AtheroNova as senior director of clinical operations...Steve Glaza joined SNBL as director of safety assessment...Rib-X Pharmaceuticals appointed Mary Szela as chair of its board of directors...Interleukin Genetics hired Scott Snyder as CMO...ArborGen named Richard I. Eisenstadt as CFO...Biothera added John P. Atkinson, M.D., to its research advisory board...Medistem appointed John Chiplin, Ph.D., to its board of directors.
David Tran joined PAC as vp of product management and marketing...Endocyte named Lesley Russell to its board of directors...Particle Sciences hired Deepak Tiwari, Ph.D., as director, formulation, and process development...Cyberonics added Bruce H. KenKnight, Ph.D., as vp, emerging therapies...Aqeel Fatmi, Ph.D., is now evp of global research and development and CSO at Patheon.
Send your People Announcements to firstname.lastname@example.org